Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option

Zhang, Honghong; Du, Xiaojing; Deng, Meiling; Yao, Dun-Chen; Wang, Zhiqiang; Yang, Qunying; Wu, Shaoxiong

doi:10.3389/fphar.2022.969565

Cited by 4 publications

(4 citation statements)

References 44 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this prospective study, a remission rate of 33.3% and a disease control rate of 66.6%, along with a PFS of 2 months and an OS of 6.5 months, were established for apatinib monotherapy in treating advanced GBM after chemoradiotherapy. The PFS and OS data of this study were inferior to previous retrospective studies [ 14 ]. The incidence of AEs was slightly higher [ 14 ].…”

Section: Discussioncontrasting

confidence: 90%

“…The PFS and OS data of this study were inferior to previous retrospective studies [ 14 ]. The incidence of AEs was slightly higher [ 14 ]. We believe the efficacy of apatinib in the treatment of recurrent GBM is worse than that of bevacizumab and temozolomide when comparing with historical data [ 21 ].…”

Section: Discussioncontrasting

confidence: 90%

“…It is not clear whether apatinib alone is equally treatment effective and has lower adverse reactions. Currently, only a few case reports and small sample size retrospective studies indicated that apatinib might be effective in the treatment of recurrent glioma [ 14 ]. Our prospective study aimed to further evaluate the efficacy and safety of apatinib monotherapy in treating recurrent GBM after chemoradiotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma

et al. 2023

View full text Add to dashboard Cite

Background and Objective Glioblastoma is a cranial malignant tumor with a high recurrence rate after surgery and a poor response to chemoradiotherapy. Bevacizumab has demonstrated efficacy in the treatment of glioblastoma by inhibiting vascular endothelial growth factor, but the efficacy of vascular endothelial growth factor receptor tyrosine kinase inhibitors varies in treating glioblastoma. This single-arm prospective study aimed to explore the efficacy and safety of the vascular endothelial growth factor receptor tyrosine kinase inhibitor apatinib in treating recurrent glioblastoma after chemoradiotherapy. Methods A total of 15 patients with recurrent glioblastoma (2016 World Health Organization grade IV) after chemoradiotherapy were enrolled in this study from September 2017 to September 2019 and treated with apatinib 500 mg once daily. Responses were evaluated according to the Response Assessment in Neuro-Oncology criteria, and adverse events were recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0. Results The overall response rate was 33.3%, and the disease control rate was 66.6%. The median progression-free survival was 2 months, and the median overall survival was 6.5 months. The apatinib dose was adjusted in seven patients because of adverse events (46.6%). The most common adverse events were thrombocytopenia (53.3%), asthenia (40%), and hand-foot syndrome (33.3%). Conclusions Apatinib might be effective in treating recurrent glioblastoma after chemoradiotherapy in terms of the overall response rate, but the efficacy is not durable and the clinical benefit is limited. The adverse effects of apatinib were acceptable. Clinical Trial Registration ChiCTR-ONC-17013098, date of registration: 24 October, 2017.

show abstract

Section: Discussioncontrasting

confidence: 90%

Section: Discussioncontrasting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma

et al. 2023

View full text Add to dashboard Cite

show abstract

“…A number of studies indicate relative efficacy of apatinib, a low-molecular-weight tyrosine kinase inhibitor, in the treatment of continued growth of glioblastoma targeting VEGFR-2 [49][50][51][52][53][54][55][56].…”

Section: Inhibitors Of Vascular Endothelial Growth Factor Receptor Ty...mentioning

confidence: 99%

Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review)

Yashin,

Yuzhakova,

Sachkova

et al. 2023

Sovrem Tehnol Med

View full text Add to dashboard Cite

Gliomas are the most common type of primary malignant brain tumors. The choice of treatments for these tumors was quite limited for many years, and therapy results generally remain still unsatisfactory. Recently, a significant breakthrough in the treatment of many forms of cancer occurred when personalized targeted therapies were introduced which inhibit tumor growth by affecting a specific molecular target. Another trend gaining popularity in oncology is the creation of patient-derived tumor models which can be used for drug screening to select the optimal therapy regimen.Molecular and genetic mechanisms of brain gliomas growth are considered, consisting of individual components which could potentially be exposed to targeted drugs. The results of the literature review show a higher efficacy of the personalized approach to the treatment of individual patients compared to the use of standard therapies. However, many unresolved issues remain in the area of predicting the effectiveness of a particular drug therapy regimen. The main hopes in solving this issue are set on the use of patient-derived tumor models, which can be used in one-stage testing of a wide range of antitumor drugs.

show abstract

Antineoplastics

2022

Reactions Weekly

View full text Add to dashboard Cite

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option

Cited by 4 publications

References 44 publications

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma

Efficacy and Safety of Apatinib in Patients with Recurrent Glioblastoma

Personalized Medicine in Brain Gliomas: Targeted Therapy, Patient-Derived Tumor Models (Review)

Antineoplastics

Contact Info

Product

Resources

About